

# Vaccination against COVID-19 in various circumstances



Age group	Recommended vaccine for primary vaccination	Number of doses primary vaccination	Period from primary vaccination to first booster	Recommended vaccine for further booster doses	Period between booster doses	Period between booster doses	Timing of vaccination according to this scheme following COVID-19 infection
60 years and older	Pfizer/Moderna/Astra/Janssen/Nuvaxovid	2	3–4 months	Pfizer/Moderna, latest/broadest-spectrum version available at any time	Pfizer/Moderna, latest/broadest-spectrum version available at any time	4 months	After recovering from the illness, a wait longer than 3–4 months not recommended
55–59 years	Pfizer/Moderna/Astra/Janssen/Nuvaxovid	2	3–4 months	Pfizer/Moderna/Nuvaxovid	Pfizer/Moderna, latest/broadest-spectrum version available at any time	4< months – #4 only recommended for at-risk groups within this age group (August 2022)	After recovering from the illness, a wait longer than 3–4 months not recommended
40–54 years	Cis-men <sup>‡</sup> : Pfizer/Moderna/Astra/Janssen/Nuvaxovid Other genders: Pfizer/Moderna/Janssen/Nuvaxovid Pregnant: Pfizer/Moderna	2	4* months	Pfizer/Moderna/Nuvaxovid	Pfizer/Moderna, latest/broadest-spectrum version available at any time	4< months – #4 only recommended for at-risk groups within this age group (August 2022)	After recovering from the illness, a wait longer than 3–4 months not recommended
18–39 years	Cis-women <sup>‡</sup> : Pfizer/Moderna/Janssen/Nuvaxovid Other genders: Pfizer/Janssen/Nuvaxovid Pregnant: Pfizer/Moderna	2	4* months	Pfizer/Moderna/Nuvaxovid	Pfizer, latest/broadest-spectrum version available at any time	4< months – #4 only recommended for at-risk groups within this age group (August 2022)	After recovering from the illness, a wait longer than 3–4 months not recommended
12–17 years	Pfizer	2	4<* months – #3 only recommended for at-risk groups within this age group (August 2022)	Pfizer/Nuvaxovid		4< months – #4 only recommended for <b>specified</b> at-risk groups within this age group (August 2022)	After recovering from the illness (primary vaccination #2 or booster dose according to the recommendations of a physician)
5–11 years	Pfizer 10 mcg/dose	2	4<* months – #3 only recommended for <b>specified</b> at-risk groups within this age group (August 2022)	Pfizer 10 mcg/dose		Further booster doses not recommended (August 2022)	After recovering from the illness (primary vaccination #2 or booster dose according to the recommendations of a physician)
0–4 years	None	--	--			--	--

<sup>‡</sup> If gender is specified here, it is due to restrictions on the use of certain vaccines in people other than that gender at the relevant age. \* May go down to 3 months due to severe immunosuppression.